Altimmune (FRA:3G0) Total Equity: €245.65 Mil (As of Mar. 2026)


FRA:3G0 Altimmune Inc FRA:3G0
28 GF Score
Price €2.57
! 2 Warning Signs
View Full Analysis

What is Altimmune Total Equity?

Altimmune FRA:3G0 -4.28% 28 Total Equity is €245.65 Mil as of Mar. 2026. GuruFocus rates FRA:3G0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Altimmune's total equity for the quarter that ended in Mar. 2026 was €245.65 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Altimmune Total Equity Historical Data

* Premium members only.

The historical data trend for Altimmune's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Total Equity Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 176.23 174.92 177.99 117.95 192.06

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.50 139.91 158.13 192.06 245.65
FRA:3G0
28GF Score
Altimmune Inc FRA:3G0
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Altimmune's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=239.059-47.002
=192.06

Altimmune's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=290.32-44.671
=245.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €245.65 Mil mean?
Altimmune (FRA:3G0) has a Total Equity of €245.65 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Altimmune and its competitors.
Is Altimmune's Total Equity too high?
Altimmune's current Total Equity is €245.65 Mil. Overall, Altimmune has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Altimmune's Total Equity compare to RGNX and TRAX?
Altimmune's Total Equity of €245.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Altimmune and its competitors. Altimmune's current Total Equity is €245.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Altimmune (FRA:3G0) has a current Total Equity of €245.65 Mil. The current Total Equity is €245.65 Mil. Altimmune's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Altimmune (FRA:3G0), the current Total Equity is €245.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altimmune Business Description

Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
28GF Score

Get the complete analysis for FRA:3G0

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57
Price